AAV Empty/Full Capsid Ratio: Analytical Methods, Quality Implications, and Development Considerations

Adeno-associated virus, or AAV, products are not made up of a single perfectly uniform particle population. In practice, AAV preparations typically contain a mixture of empty capsids with no packaged vector genome, full capsids carrying the intended genome, and often partially filled or otherwise heterogeneous particles as well. Because of that, the empty/full capsid ratio has become a central analytical parameter in AAV development and quality assessment. Recent reviews of AAV analytics describe capsid-content analysis as a key part of product characterization, alongside titer, identity, potency, purity, and genome integrity.

What the empty/full capsid ratio actually means

In simple terms, the empty/full capsid ratio describes how much of an AAV preparation is composed of capsids without packaged therapeutic DNA versus capsids that contain the intended vector genome. In reality, this is often better understood as an empty/partial/full distribution, because many lots contain intermediate species rather than only two clean particle classes. Reviews and primary studies alike now emphasize that partial particles are common enough that binary “empty versus full” language can oversimplify the true composition of a sample.

This distinction matters because capsid-content measurements are not the same as vector genome titer. A genome-based assay such as qPCR or ddPCR can estimate how many genomes are present in a sample, but it does not directly reveal how many physical capsids are empty, partial, or full. Likewise, total capsid assays quantify the number of capsid particles but do not indicate what is packaged inside them. Empty/full analysis fills that gap by addressing the relationship between physical particles and packaged nucleic acid content.

Why the ratio matters

The empty/full capsid ratio matters first because it affects how dose is interpreted. If a preparation contains a high proportion of empty particles, the number of total capsids administered may be much higher than the number of capsids actually carrying the therapeutic genome. That can complicate comparisons across lots and create a mismatch between nominal dose and effective gene-delivery capacity. Recent analytical reviews therefore frame capsid-content analysis as an important quality attribute for making sense of AAV product composition.

It also matters because empty and partial capsids can influence process understanding and lot consistency. Capsid-content distributions reflect upstream packaging efficiency, vector design, manufacturing conditions, and downstream purification performance. For that reason, empty/full analysis is widely used not only for final product characterization but also during process development, purification optimization, stress studies, and lot-to-lot comparability work. Comparative analytical studies have explicitly evaluated how methods perform for untreated and stressed AAV samples, underscoring that capsid-content analysis is relevant across the full product lifecycle rather than only at release.

A third reason is that capsid-content composition has potential implications for safety and immunogenic burden, although that relationship should not be overstated. Empty capsids can contribute additional viral protein exposure without delivering therapeutic cargo, and reviews frequently discuss them in the context of potency, dosing efficiency, and immunogenicity considerations. At the same time, empty/full ratio alone does not predict clinical outcome; it is one important quality attribute within a broader analytical framework.

Why empty and partial capsids arise

Empty and partial capsids arise because AAV packaging is not perfectly efficient. The process of genome replication, rescue, encapsidation, and maturation can yield a heterogeneous population of particles, especially when vector design approaches the practical packaging limit or when production and purification conditions are suboptimal. Reviews of rAAV process and product characterization note that the fraction of capsids containing a complete genome is shaped by both upstream and downstream variables, not by purification alone.

Sequence and genome architecture also matter. AAV lots can contain not only intended full genomes, but also truncated or partially packaged species, and those populations can shift depending on cassette design and manufacturing context. That is one reason capsid-content analysis increasingly sits alongside genome-integrity analysis in modern AAV characterization strategies.

How the empty/full ratio is measured

No single assay is perfect for every stage of development, so modern AAV characterization often uses orthogonal methods. Recent reviews describe analytical ultracentrifugation, electron microscopy, chromatography-based methods, electrophoretic methods, charge-detection or native mass spectrometry, and mass photometry as the main analytical families used to assess capsid content. Each provides a different balance of resolution, throughput, sample requirement, and ease of implementation.

Analytical ultracentrifugation

Sedimentation velocity analytical ultracentrifugation (SV-AUC) remains one of the most established methods for capsid-content analysis. Because it separates particles based on sedimentation behavior, it can resolve empty, partial, and full AAV species in a label-free manner and has long been treated as a benchmark technique in the field. Comparative method papers and reviews consistently describe AUC as a high-resolution approach for distinguishing capsid-content populations.

Its strengths are precisely why AUC is often referred to in practice as a gold-standard method. At the same time, it is relatively low-throughput, instrument-intensive, and method-dependent, which can limit its routine use during fast process screening. That is why many groups continue to rely on AUC for high-confidence characterization while also adopting faster orthogonal methods for development support.

Electron microscopy

Electron microscopy, including negative-stain TEM and cryo-EM or cryo-TEM workflows, can directly visualize capsid populations and has long been used to estimate empty and full particles. It provides intuitive visual evidence of particle morphology and occupancy, which is one reason it remains valuable in the field. Recent method development studies continue to refine cryo-TEM-based approaches for quantifying empty capsid proportions.

However, EM-based methods also have important limitations. Reviews note that staining, imaging conditions, classification criteria, and data-processing choices can affect quantification, and structural studies indicate that the capsid shells of empty and full particles are highly similar at the structural level. As a result, EM is powerful, but it is not always the simplest route to routine, high-throughput quantitative analysis.

Chromatographic and electrophoretic methods

Chromatographic and electrophoretic methods have gained attention because they can be faster and more scalable than AUC. Anion-exchange chromatography (AEX/IEX) can separate empty and full particles because genome packaging alters particle properties enough to shift chromatographic behavior, and primary method-development studies have shown good agreement with AUC in some contexts, even if AUC generally retains better intrinsic resolution.

Likewise, electrophoretic and microfluidic methods, including capillary-based approaches, have been developed to estimate empty/full distributions more rapidly and with smaller sample demands. These methods can be valuable for screening and comparability workflows, but their performance depends on serotype, buffer conditions, calibration strategy, and the degree to which partial particles are present.

Mass spectrometry and charge-detection approaches

Mass-based single-particle techniques are increasingly important in AAV analytics. Charge-detection mass spectrometry (CD-MS) can directly measure heterogeneous capsid populations and is especially useful when partial and overfilled species complicate interpretation. Recent studies describe CD-MS as a sensitive method for analyzing heterogeneous AAV assemblies and tracking capsid-content populations across process stages. Native mass spectrometry approaches have also been reported for rapid empty/full assessment without extensive sample preparation.

These approaches are particularly valuable because they do not rely only on indirect separation behavior; they provide mass-resolved information at the particle level. Their limitations are more practical than conceptual, including instrument access, workflow complexity, and the need for careful data analysis.

Mass photometry

Mass photometry has emerged as a fast, low-sample, label-free method for quantifying empty, partial, and full AAV particles. Primary studies in recent years have shown good agreement with AUC for certain applications, while offering much faster measurement and simpler operation. This has made mass photometry increasingly attractive for upstream screening, purification monitoring, and rapid comparability assessment.

That said, mass photometry should be treated as complementary rather than universally interchangeable with every other method. Its performance depends on sample composition and calibration, and different analytical questions may still favor AUC, CD-MS, chromatography, or sequencing-based orthogonal characterization. The broader trend in the literature is not toward one universal assay, but toward fit-for-purpose method selection with orthogonal confirmation where needed.

What the empty/full ratio can and cannot tell you

Capsid-content analysis is extremely informative, but it does not answer every quality question on its own. A favorable empty/full ratio does not guarantee correct genome structure, potency, purity, or safety. Conversely, a sample with a less favorable ratio may still perform differently depending on transgene design, infectivity, route of administration, and biological context. High-quality reviews therefore position empty/full analysis as one important critical quality attribute, but not a standalone surrogate for total product performance.

It is also important to interpret “full” carefully. Depending on the analytical method, a particle classified as full may contain the intended genome, a heterogeneous genome population, or an aberrant packaged nucleic acid species of similar mass or sedimentation behavior. This is why capsid-content analysis is often most informative when paired with genome-integrity testing and genome-titer assays.

Practical implications for AAV development

From a development standpoint, the most useful view is that empty/full analysis is both a product-quality readout and a process-learning tool. During early development, it can help compare construct designs, transfection conditions, harvest timing, and purification strategies. In later stages, it supports comparability, analytical control strategy, and a more complete understanding of lot quality. The literature increasingly treats capsid-content analysis as part of an integrated analytical package rather than a standalone specialty test.

The bottom line is that the empty/full capsid ratio matters because it connects physical particle burden to functional genome delivery. Modern AAV products are heterogeneous enough that this measurement cannot be inferred from titer alone, and modern analytics are advanced enough that it no longer needs to be. The strongest characterization strategies therefore use the method best suited to the question at hand and, when needed, confirm findings with orthogonal techniques.

At PackGene, we support AAV programs with integrated capabilities spanning AAV production, analytical development, and specialized characterization workflows. PackGene’s current AAV analytical offerings include AUC-based empty/full capsid ratio testing, broader AAV analytical testing services, and educational resources covering methods such as AUC, TEM, DLS, and mass photometry for quantitative capsid-content assessment. For teams optimizing vector quality during research, process development, or GMP-oriented programs, those capabilities can help build a more complete and method-appropriate view of AAV capsid composition and product quality